China Clears CCR5 Inhibitor Sarac for Clinical Trials, Phase 2 in Multiple Sclerosis Planned
Start here
China's drug regulator has approved Sarac, a CCR5 inhibitor developed with the Shanghai Institute of Materia Medica, to enter clinical trials, with a phase 2 multiple sclerosis trial planned next. The programme builds on neuroimmunology work showing that myelin-reactive T cells home to the bone marrow and drive CCR5-mediated skewing of hematopoietic stem cells toward myeloid lineages in multiple sclerosis. Related research has also implicated bone-marrow mechanisms in intracerebral hemorrhage and in stroke-associated pneumonia, where CCR2-driven migration of hematopoietic stem cells to the lung plays a role. Sarac's approval marks the transition of this CCR5 biology into clinical testing. The design, timing and results of the planned phase 2 multiple sclerosis trial remain open questions.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- youtube.comPickCCR5 Inhibitor Sarac Cleared for Trials in China, Phase 2 in MS Planned
An expert talk on neuroimmunology covers how myelin-reactive T cells home to bone marrow and drive CCR5-mediated myeloid skewing of hematopoietic stem cells in multiple sclerosis, plus bone-marrow mechanisms in intracerebral hemorrhage and stroke-associated pneumonia involving CCR2-driven HSC migration to the lung. A CCR5 inhibitor, Sarac, developed with the Shanghai Institute of Materia Medica, has been approved by China's FDA to enter clinical trials, with a phase 2 trial (Sarac MS) in multiple sclerosis planned next.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 18 04:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.